Navidea Biopharmaceuticals released Phase IIB clinical testing results recently and based on these positive results plans to speak with FDA about commencing Phase III testing. 99mTc labeled Tilmanocept demonstrated its ability to image joints impacted by rheumatoid arthritis (RA). Should this radiopharmaceutical successfully finish FDA clinical trials and be marketed, nuclear medicine imaging may be able to better judge the potential for success of treatment regimens for RA. Read more.